Cannabis and Migraines: What You Need to Know

Cannabis research for migraine has advanced beyond patient reports: a randomized trial published in Headache found benefit from a specific THC-and-CBD preparation for treating individual attacks. That is encouraging evidence, but it does not establish cannabis as a routine preventive treatment or show that every product works.

Cannabis can also be associated with headaches. A new or worsening headache after use should not automatically be blamed on dehydration, food, or a “cannabis hangover.” The symptoms, timing, other medicines, and pattern of cannabis use deserve assessment.

What the New Randomized Trial Found

The 2026 randomized crossover trial enrolled 92 participants, who treated 247 migraine attacks. It compared vaporized flower containing 6% THC, 11% CBD, their combination, or placebo.

In the reported modified intention-to-treat analysis, the combination achieved pain relief at two hours in 67.2% of treated attacks, versus 46.6% with placebo. Complete pain freedom occurred in 34.5% versus 15.5%. THC alone improved pain relief but not the two-hour pain-freedom endpoint; CBD alone was not superior to placebo on those endpoints.

No serious adverse events were reported, but that does not establish long-term safety. The study addressed acute attacks, not prevention, and did not compare cannabis with standard migraine medicines. Its findings cannot be transferred directly to commercial vape oils, stronger flower, or edibles. Larger studies and repeated-use safety data are needed.

What Earlier Observational Research Can Tell Us

A 2016 retrospective review examined records from 121 adults at two Colorado medical-cannabis clinics. Average migraine frequency fell from 10.4 to 4.6 headaches per month, rather than from 4.6 to 1.4 as previously reported here.

Without a randomized comparison group, that change cannot establish how much improvement cannabis caused. Other treatments, patient selection, and changes over time can affect the result. Observational improvements are useful reasons for further research, not proof of a preventive regimen.

The previously cited 2017 paper is a review of existing literature, not an independent clinical trial confirming the same outcome. Repeating a study inside a review does not create a second set of patients.

Can Cannabis Cause Headaches?

Health Canada lists headache among possible cannabis side effects and among withdrawal symptoms after stopping use. This does not mean every headache following cannabis is caused by it, but it makes dismissing that possibility inappropriate.

Sleep disruption, missed meals, alcohol, environmental exposures, and an underlying headache disorder may also be relevant. Dry mouth does not, by itself, diagnose dehydration. A headache does not identify pesticides, and an “organic” label cannot establish that a product is contaminant-free.

Keep a record of headache timing, severity, associated symptoms, cannabis amounts and products, and other medicines. If headaches repeatedly follow a particular product or pattern of use, discuss that pattern with a clinician rather than assuming a different strain will solve it.

Frequent Use and Medication-Overuse Headache

A 2021 chart-based study of 368 people with chronic migraine found medication-overuse headache in 81% of current cannabis users and 41% of nonusers. Cannabis use was also associated with opioid use.

This association does not prove that cannabis caused medication-overuse headache: people with more difficult symptoms may use more treatments, and other factors can contribute. It is still a reason to review frequent cannabis use alongside all acute headache medicines, rather than treating cannabis as exempt from an overuse assessment.

The American Migraine Foundation explains that overuse thresholds depend on the medicine. A clinician can review treatment days, diagnosis, and preventive options; do not apply one universal limit to every product or stop prescribed medicines without a plan.

Is There a Best Product, Dose, or Delivery Method?

These studies do not establish a general cannabis dose for migraine. A research preparation’s percentage is not a dosing instruction for a different product, and a faster onset does not prove that vaping is the most effective or safest treatment.

Smoking exposes the lungs to combustion products, and vaping also carries risks. Oral products have different timing and metabolism. None should be presented as a proven preventive treatment merely because its effects last longer.

High CBD content is not a guarantee against headache or THC-related impairment. As our review of CBD-and-THC interaction studies explains, the combination’s effects depend on amounts, route, and context.

Questions to Discuss With a Clinician

• Is this migraine, another primary headache disorder, or a headache requiring investigation?
• Which established acute and preventive treatments are appropriate, and have they had an adequate trial?
• Could cannabis, withdrawal, or frequent medication use be contributing to the headache pattern?
• How would any proposed cannabis product interact with existing medicines and affect driving or work?
• What measurable improvement would justify continuing it, and what adverse effects would prompt stopping?

A treatment plan should distinguish relief of an individual attack from reducing future attacks. Track both headache burden and adverse effects, rather than judging benefit only by feeling relaxed or intoxicated.

When a Headache Needs Urgent Attention

Seek emergency care for a sudden, extremely painful headache, or a headache with new weakness, difficulty speaking, a seizure, or major confusion. NHS headache guidance identifies these as emergency warning signs. Do not assume they are an ordinary migraine or a cannabis after-effect.

Cannabis may have a role in future migraine care, but the evidence supports a careful discussion about specific preparations and outcomes. It does not support dismissing cannabis-related headaches or recommending self-directed daily use.